ReviewJournal of clinical medicine2026
Macular Holes Secondary to Macular Telangiectasia Type 2: Pathogenesis, Clinical Features, Imaging and Surgical Management.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Full-thickness macular holes (FTMHs) are a rare but recognized complication of macular telangiectasia type 2 (MacTel2). Unlike idiopathic FTMHs, which are primarily driven by vitreofoveal traction, MacTel2-associated holes appear to arise predominantly from progressive neurodegenerative changes. Müller cell dysfunction, intraretinal cavitation, and outer retinal atrophy progressively compromise foveal architecture, ultimately predisposing to tissue dehiscence and full-thickness defects. Although vitreofoveal traction may contribute in individual cases, it is unlikely to be the principal mechanism in most affected eyes. Surgical treatment remains challenging, as current evidence is limited to case reports and small case series. Internal limiting membrane (ILM) flap techniques and, in selected cases, retinal graft or amniotic membrane transplant procedures have yielded encouraging anatomical closure rates, whereas conventional ILM peeling alone appears less predictable. Importantly, restoration of foveal continuity does not necessarily result in meaningful visual improvement, particularly in eyes with established photoreceptor and outer retinal damage. The durability of anatomical repair may be further compromised by continued disease progression. Persistent Müller cell dysfunction, intraretinal cavitation, and progressive outer retinal atrophy can undermine foveal support and lead to recurrent architectural disruption, including reopening of a previously closed hole. Although late recurrence has been documented, its incidence and determinants remain poorly defined because of the limited size and heterogeneity of the available literature. Visual prognosis appears to be determined largely by the amount of structurally and functionally viable retinal tissue remaining at the time of intervention. Smaller defects, less extensive cavitation, and preservation of the external limiting membrane and ellipsoid zone are associated with greater potential for visual recovery. In contrast, extensive cavitation, advanced outer retinal atrophy, and substantial Müller cell or photoreceptor loss are associated with limited functional improvement and may compromise long-term anatomical stability. Overall, a FTMH secondary to MacTel2 should be regarded as a distinct form of macular hole in which surgical repair occurs against a background of ongoing macular neurodegeneration. Preoperative evaluation of hole dimensions, foveal cavitation, and outer retinal integrity may assist in prognostication and in identifying eyes with the greatest likelihood of achieving durable anatomical closure and meaningful visual recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.